Roche Holding AG said growth momentum for its Covid-19 testing business will probably abate in coming months, signaling a leveling off of the jackpot that fueled sales lately.
Roche’s diagnostics unit swiftly developed a wide array of tests in response to the pandemic, buoying sales and making up for a more difficult time at the pharmaceuticals division, where aging cancer medicines face competition.
